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Background/aim: The aim of the study was to evaluate the effect of Controlling Nutritional Status (CONUT) score on the prognosis in
patients with diffuse large B-cell lymphoma (DLBCL).
Materials and methods: The present study was a retrospective study. The CONUT score was calculated based on serum albumin, total
cholesterol and lymphocyte levels. This study included a total of 266 patients, 131 (49.2%) were female and 135 (50.8%) were male. The
median follow-up period was 51 months (range: 1–190).
Results: The median age was 64 years. The cut off CONUT was 1.5. There was a significant difference between patients with high (≥ 2)
or low (< 2) CONUT scores in terms of overall survival (OS) and progression-free survival (PFS). The 5-year OS and PFS in patients
with high CONUT score was 52.1% and 49.7%. The 5-year OS and PFS in patients with low CONUT score was 79.8% and 75.6% (p <
0.001). In the multivariate analysis for OS, age ≥ 65 years (HR = 1.80, p = 0.028), Eastern Cooperative Oncology Group (ECOG) > 1 (HR
= 2.04, p = 0.006), stage IIIA–IVB disease (HR = 2.75, p = 0.001) and the CONUT score (HR = 1.15, p = 0.003) were found statistically
significant. In the multivariate analysis for PFS, age ≥ 65 years (HR = 2.02, p = 0.007), stage IIIA–IVB disease (HR = 2.42, p = 0.002) and
the CONUT score (HR = 1.19, p = 0.001) were found to be significant parameters.
Conclusion: High CONUT score reduces OS and PFS in DLBCL. CONUT score is an independent, strong prognostic index in patients
with DLBCL.
Key words: Lymphoma, Controlling Nutritional Status score, survival, prognosis

1. Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common Non-Hodgkin lymphoma (NHL), constituting
approximately 30%–40% of all NHL patients. Although
it is an aggressive tumour, 60%–70% of the patients
are cured with standard rituximab, cyclophosphamide,
hydroxydaunorubicin, vincristine and prednisone
(R-CHOP) chemotherapy [1]. However, approximately
one-third of the patients are refractory to standard
R-CHOP therapy. Gene expression profile and
International Prognostic Index (IPI) are useful parameters
in identifying high-risk patients [2]. The relationship

between prognostic nutritional index and prognosis has
been shown in patients with DLBCL [3].
The Controlling Nutritional Status (CONUT) score
is a significant indicator used to identify patients with
malnutrition in recent years. This score is calculated based
on serum albumin, total cholesterol and lymphocyte
counts. Serum albumin, total cholesterol and lymphocyte
counts indicate protein reserve, calorie status and immune
function, respectively. It is known that high CONUT
score has an effect on the prognosis in patients who have
undergone gastrointestinal surgery, cardiovascular disease,
end-stage renal disease and malignant tumours [4-7].
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In our study, we evaluated the survival and prognostic
impact of the CONUT score in patients with DLBCL. The
aim of the study was to evaluate the effect of Controlling
Nutritional Status (CONUT) score on the prognosis in
patients with diffuse large B-cell lymphoma (DLBCL).
2. Materials and methods
2.1. Patients
The present study included 266 DLBCL patients who were
followed between 2012 and 2020 in the Department of
Hematology, Faculty of Medicine, Pamukkale University.
The study cohort was retrospectively enrolled. The median
follow-up period was 51 months (range: 1–190). The
final follow-up date was May 2020. The present study
was approved by the Ethics Committee of the Faculty of
Medicine, Pamukkale University. No procedures were
performed, and no interventions were made during the
study because of the retrospective study design. Patients
with primary central nervous system lymphoma, human
immunodeficiency virus-associated lymphoma and only
palliative treatment were excluded. Patients who receive
lipid lowering therapy were excluded. As our centre is
not performing allogeneic stem cell transplantation,
patients who received allogeneic stem cells were excluded.
Performance status (PS) was evaluated based on the Eastern
Cooperative Oncology Group (ECOG) criteria. National
Comprehensive Cancer Network International Prognostic
Index (NCCN-IPI) was determined based on the age at
the time of diagnosis, serum lactate dehydrogenase (LDH)
levels, PS, stage and extranodal involvement. Normal
range of LDH was 135–225 U/L. The values above 225 U/L
were considered high.
2.2. CONUT score
The CONUT score was calculated based on serum albumin
concentration, total lymphocyte count and total cholesterol
levels. Albumin concentrations of ≥ 3.50 g/dL, 3.00–3.49
g/dL, 2.50–2.99 g/dL and < 2.50 g/dL were scored as 0,
2, 4 and 6 points, respectively. Total lymphocyte counts
of ≥ 1600 mm3, 1200–1599 mm3, 800–1199 mm3 and <
800 mm3 were scored as 0, 1, 2 and 3 points, respectively.
Total cholesterol levels of ≥ 180 mg/dL, 140–179 mg/dL,
100–139 mg/dL and < 100 mg/dL were scored as 0, 1, 2
and 3 points. The CONUT score was calculated based on
the addition of points albumin, total lymphocyte and total
cholesterol at the time of diagnosis.
2.3. About chemotherapy
R-CHOP (rituximab 375 mg/m2 on day 1, cyclophosphamide
750 mg/m2 on day 2, doxorubicin 50 mg/m2 on day 2,
vincristine 1.4 mg/m2 on day 2 and prednisone 100 mg/
m2 on days 1–5) or R-mini-CHOP (at a 25% reduced dose)
chemotherapy was given to patients with DLBCL every 21
days based on their age, PS and comorbidities. The median

age of patients treated with R-mini-CHOP chemotherapy
was 79 years (65–91 years). The pathological phenotype of
patients treated with DA-REPOCH (rituximab 375 mg/m2
on day 1, etoposide 50 mg/m2 on days 1–4, doxorubicin
10 mg/m2 on days 1–4, vincristine 0.4 mg/m2 on days 1–4,
cyclophosphamide 750 mg/ m2 on day 5 and prednisone
100 mg/m2 on days 1–5) chemotherapy was non-germinal.
DA-REPOCH chemotherapy regimen was repeated every
21 days.
2.4. Statistical analyses
Overall survival (OS) was defined as the period between
the time of diagnosis and the last follow-up or death.
Progression-free survival (PFS) was defined as the period
between the time of diagnosis and the last follow-up,
progression, relapse or death. Normality was tested using
the Shapiro–Wilk test. Mann–Whitney U test was used
for nonparametric distribution comparison. Kruskal–
Wallis variance test was used for comparing three different
chemotherapy regimens. OS and PFS were predicted using
the Kaplan–Meier method and were compared using the
log-rank test. We performed univariate and multivariate
analyses for OS and PFS using the COX regression model.
The correlation between the CONUT score and OS and
PFS was analysed using the Spearman test. The receiver
operating characteristic (ROC) curve analysis revealed
the distinctive cut-off value for CONUT. All data were
analysed using the SPSS Statistics version 25.0 (IBM SPSS
Statistics 25 software; IBM Corp., Armonk, NY, USA) A p
value of <0.05 was considered statistically significant.
3. Results
3.1. Characteristics of patients
The present study included a total of 266 patients with
DLBCL 131 (49.2%) females and 135 (50.8%) males. The
median age was 64 years (range: 23–91). The median
follow-up period was 51 months (range: 1–190). For initial
therapy, 223 (83.8%), 12 (4.5%) and 31 (11.7%) patients
received R-CHOP, R-CHOP-mini and DA-REPOCH
therapy regimes, respectively. The pathological phenotype
of patients treated with DA-REPOCH therapy was nongerminal (11.7%). The patients were evaluated based on
the NCCN-IPI. The patients with low or low-intermediate
risk were categorised as low-IPI and those with highintermediate or high risk were categorised as high IPI.
The median number of cycles of chemotherapy was 6
(range, 1–10). The demographic and laboratory data of the
patients are presented in Table 1.
We recorded remission, refractory and relapsed
disease states from 266 patient files. Following the initial
treatment, 168 (63.2%) patients were in remission. The
disease progression was identified using positron emission
tomography (PET-CT) or computed tomography (CT).
Ninety-five patients (35.7%) died during the study. The
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Table 1. Patients characteristics.

involvement, extranodal disease, high risk NCCN-IPI and
stage IIIA–IVB (p = 0.001) (Table 3).
median /(min-max)

Age (year)

64 (23– 91)

ECOG

0 (0–4)

White blood cell(x109/L)

7.78 (1.73–30.6)

Lymphocytes (x109/L)

1680 (430–5890)

Hemoglobin (gr/dL)

12.75 (6.4–16.9)

Platelet (x10 /L)

269.5 (34–903)

AST ( IU/L)

19 (5–195)

ALT (IU/L)

17 (3–195)

Total bilirubin (mg/dL)

0.43(0.09–5.8)

Uric acid (mg/dL)

4.45(1.38–22)

9

Creatinine (mg/dL)

0.73(0.35–6.84)

LDH ( U/L)

213.5(114–3855)

Albumin (mg/dL)

4.18(1.72–5.15)

Total cholesterol (mg/dL)

190 (59–780)

CONUT score

1 (0–11)

ECOG: Eastern Cooperative Oncology Group
CONUT: Controlling Nutritional Status

median CONUT scores were 1 (range: 0–11). The median
CONUT scores in patients with progressive disease
were 2.5. The median CONUT scores in patients with
no progressive disease were 1. The CONUT scores were
higher in patients with progressive disease (p = 0.001).
The comparison between the CONUT score and clinical
characteristics and laboratory parameters was shown in
Table 2.
There was a statistically significant difference between
the CONUT scores and prognostic factors. (Such as age,
ECOG, clinical stage, LDH level, extranodal disease, bone
marrow involvement, NCCN-IPI and progressive disease
(Table 2). There was no significant difference between the
patients’ sex and first-line chemotherapy and the CONUT
scores.
The (ROC) curve analysis found the distinctive cutoff value for CONUT score to be 1.5 (The state of alive or
censored from diagnosis and died within from diagnosis)
(AUC = 0.74) (95% confidence interval Cl, 67.3.80.4)
(73,4% sensitivity, 67.4% specifity) (Figure 1).
Therefore, we considered a CONUT score of ≥ 2 as
high and a score of < 2 as low. There was a statistically
significant difference for the age (< 65 and ≥ 65 years)
parameter between patients with a CONUT score >2
and those without (p = 0.002). There was a statistically
significant difference between the patients with high (≥ 2)
and low (< 2) CONUT scores and PS, LDH, bone marrow
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3.2. Overall survival and progression-free survival
In the univariate analysis for OS, age ≥ 65 (HR 3.19, 95%
Cl 2.03–5.01, p = 0.001), ECOG > 1 (HR 1.97, 95 Cl%
1.69–2.31, p = 0.001), bone marrow infiltration (HR 3.02,
95% Cl 2.05–4.98, p = 0.001), presence of extranodal
involvement (HR 1.61, 95% Cl 1.07–2.43, p = 0.023), stage
IIIA–IVB disease (HR 4.37, 95% Cl 2.86–6.69, p = 0.001),
high IPI risk (HR 4.83, 95% Cl 3.17–7.36, p = 0.001) and
CONUT scores (HR 1.23, 95% Cl 1.15–1.31, p = 0.001)
were found to be statistically significant. In the univariate
analysis for PFS, age ≥ 65 (HR 3.17, 95% Cl 2.04–4.92,
p = 0.001), ECOG > 1 (HR 1.94, 95% Cl 1.65–2.27, p =
0.001), increased LDH level (HR 1.52, 95% Cl 1.02–2.28,
p = 0.038), bone marrow infiltration (HR 3.04, 95% Cl
1.96–4.72, p = 0.001), stage IIIA–IVB disease (HR 4.07,
95% Cl 2.68–6.18, p = 0.001), high IPI risk (HR 4.52, 95%
Cl 3–6.82, p = 0.001) and CONUT scores (HR 1.24, 95%
Cl 1.15–1.33, p = 0.001) were found to be significant (Table
4).
In the multivariate analysis for OS, age ≥ 65 (HR 1.80,
95% Cl 1.06–3.05, p = 0.028), ECOG >1 (HR 2.04, 95%
Cl 1.22–3.42, p = 0.006), stage IIIA–IVB disease (HR
2.75, 95% Cl 1.51–4.99, p = 0.001) and the CONUT score
(HR 1.15, 95% Cl 1.04–1.26, p = 0.003) were found to be
statistically significant. In the multivariate analysis for PFS,
age ≥ 65 (HR 2.02, 95% Cl 1.21–3.37, p = 0.007) and stage
IIIA–IVB disease (HR 2.42, 95% Cl 1.36–4.31, p = 0.002)
and CONUT score (HR 1.19, 95% Cl 1.08–1.31, p = 0.001)
were found to be significant (Table 5). There was a negative
correlation between the CONUT score and OS (r = −0.303,
p = 0.001) and PFS (r = −0.329, p = 0.001). As the CONUT
score increases, OS and PFS decrease. In addition, there
was significant difference between the patients with high
(≥ 2) and low (< 2) CONUT scores in terms of OS and
PFS. Five-year OS and PFS in patients with high CONUT
scores were 52.1% and 49.7%, respectively. Five-year OS
and PFS in patients with low CONUT scores were 79.8%
and 75.6%, respectively (p < 0.001) (Figures 2,3).
4. Discussion
CONUT score is for scoring to assess the nutritional
and immune status. The CONUT score has been shown
to be associated with disease progression and mortality
in cancer patients. Poor nutritional status both increases
chemotherapy-induced toxicity and negatively affects the
response to chemotherapy [8,9]. Our study found that
OS and PFS decreased in patients with high CONUT
scores. We have shown that a high CONUT score is an
independent, strong prognostic index in patients with
DLBCL.
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Table 2. The comparation between the CONUT score and patients’ characteristics
and laboratory parameters.
CONUT score

p

Median (min–max)
Age <65

1 (0–9)

Age≥65

2 (0–11)

Sex (female)

1 (0–11)

Sex (male)

1 (0–10)

ECOG<1

1 (0–8)

ECOG≥1

2 (0–11)

LDH normal

1 (0–10)

LDH>normal

2 (0–11)

Bone marrow involvement (-)

1 (0–11)

Bone marrow involvement (+)

3 (0–7)

Extranodal disease (-)

1 (0–9)

Extranodal disease (+)

2 (0–11)

Stage (IA-IIB)

0 (0–11)

Stage (IIIA-IVB)

2 (0–9)

IPI (low,low intermediate)

0 (0–8)

IPI (high intermediate,high)

3 (0–11)

Progressive disease (-)

1 (0–9)

Progressive disease (+)

2.5 (0–11)

RCHOP chemotherapy

1 (0–11)

RCHOP-mini chemotherapy

1 (0–10)

DA REPOCH chemotherapy

2 (0–9)

p = 0.001
p = 0.667
p = 0.001
p = 0.001
p = 0.001
p = 0.001
p = 0.001
p = 0.001
p = 0.001

p = 0.153

ROC Curve

1.0

Sensitivit y

0.8

0.6

0.4

0.2

0.0

0.0

0.2

0.6
0.4
1 - Specificity

0.8

1.0

(AUC = 0.74) (95% confidence interval Cl. 67.3-80.4)

Figure 1. The CONUT score by ROC analysis.
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Table 3. Comparing between the CONUT score low (< 2) and high (≥ 2) patients.

Age

Total
(n = 266)

Conut < 2
(n = 146)

Conut ≥ 2
(n = 120)

< 65

136 (51.1%)

87

49

≥ 65

130 (48.9%)

59

71

Female

131 (49.3%)

67

64

Male

135 (50.7%)

79

56

<1

158 (59.4%)

105

43

≥1

108 (40.6%)

41

67

normal

136 (51.1%)

91

45

> normal

130 (48.9%)

55

75

Bone marrow
involvement

-

217 (81.6%)

137

80

+

49 (18.4%)

9

40

Extranodal
Disease

-

133 (50%)

93

40

+

133 (50%)

53

80

IA-IIB

159 (59.8%)

114

45

IIIA-IVB

107 (40.2%)

32

75

IPI (low,low intermediate)

167 (62.8%)

129

38

IPI (high intermediate,high)

99 (37.2%)

17

82

Sex
ECOG
LDH

Stage

p
p = 0.002
p = 0.227
p = 0.001

p = 0.001
p = 0.001

p = 0.001
p = 0.001
p = 0.001

Table 4. Univariate analysis for overall survival and progression free survival.
Overall Survival
HR

95%Cl

p

HR

95%Cl

p

Age ≥ 65

3.19

2.03–5.01

0.001

3.17

2.04–4.92

0.001

Sex

0.79

0.53–1.18

0.250

0.84

0.56–1.25

0.384

ECOG > 1

1.97

1.69–2.31

0.001

1.94

1.65–2.27

0.001

LDH

1.49

0.99–2.25

0.053

1.52

1.02–2.28

0.038

Bone marrow involvement
Extranodal
Disease
Stage (IIIA-IVB)

3.2

2.05–4.98

0.001

3.04

1.96–4.72

0.001

1.61

1.07–2.43

0.023

1.42

0.95–2.12

0.085

4.37

2.86–6.69

0.001

4.07

2.68–6.18

0.001

IPI(low- high)

4.83

3.17–7.36

0.001

4.52

3– 6.82

0.001

CONUT score

1.23

1.15–1.31

0.001

1.24

1.15–1.33

0.001

Malnutrition is observed in 30%–85% of patients
with advanced stage cancer. There are studies regarding
loss of weight, sarcopenia, low body mass index and
low serum albumin to define malnutrition in patients
with malignancy [10,11]. Albumin is the most abundant
plasma protein in the blood and synthesised in the liver.
Serum albumin is known to be associated with prognosis
in various cancer types. Lymphocytes include CD4, CD8
T cells, natural killer cells, gamma–delta T cells and B
cells. Decreased lymphocyte count is associated with
impaired immunity, which causes the progression of the
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Progression Free Survival

tumour [9,12]. CONUT score is calculated by measuring
serum albumin, lymphocyte count and total cholesterol
levels. Recently, the CONUT score, which is a nutritional
index, has been used for the definition of malnutrition. It
has been reported that the CONUT score is a prognostic
factor that has an effect on survival in colorectal, gastric,
oesophageal, hepatocellular, cholangiocarcinoma and lung
cancers [13–19].
There are a limited number of studies showing the
effect of CONUT score in haematological malignancies.
The studies by Okamoto et al. and Ureshino et al. found
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Table 5. Multivariate analysis for overall survival and progression free survival.
Overall Survival

Progression Free Survival

HR

95%Cl

p

HR

95%Cl

p

Age ≥ 65

1.80

1.06–3.05

0.028

2.02

1.21–3.37

0.007

LDH

1.03

0.63–1.68

0.890

1.21

0.76–1.93

0.420

ECOG > 1

2.04

1.22–3.42

0.006

1.65

0.99–2.76

0.053

Bone marrow involvement
Extranodal
Disease
Stage (IIIA-IVB)

1.02

0.53–1.94

0.939

1.26

0.67–2.35

0.468

0.73

0.39–1.36

0.335

0.61

0.34–1.12

0.113

2.75

1.51–4.99

0.001

2.42

1.36–4.31

0.002

IPI(low- high)

1.38

0.61–3.08

0.432

1.32

0.60–2.89

0.478

CONUT score

1.15

1.04–1.26

0.003

1.19

1.08–1.31

0.001

(AUC = 0.74) (95% confidence interval Cl, 67.3–80.4)

1.0

0.8

0.6

0.4

CONUT<2 (low)

0.2

CONUT≥2 (high)

0.0
.00

50.00

100.00

Survival (months)

150.00

200.00

Figure 2. Comparing overall survival (OS) and CONUT score
(< 2) and (≥ 2).

that the CONUT score is a prognostic factor in multiple
myeloma and T cell leukaemia/lymphoma, respectively
[5,8]. There are only studies by Nagata et al. and Matsukawa
et al. on the prognostic significance of CONUT score
in patients with DLBCL [20,21]. We also evaluated the
difference of CONUT score with prognostic factors. There
was a significant difference between high CONUT scores
and older age, worsened PS, increased LDH, bone marrow
involvement and extranodal disease, stage IIIA–IVB and
high risk NCCN-IPI (high-intermediate, high). We found

the CONUT score higher in patients with progressive
disease than in those without. Our study found a negative
correlation between CONUT score and OS and PFS. We
found that as the CONUT score increased, OS and PFS
decreased. In addition, there was a significant difference
between patients with high (≥ 2) or low (< 2) CONUT
scores in terms of 5-year OS and PFS. Our results were
similar to those in the studies by Nagata et al. and
Matsukawa et al. [20,21]. We showed that the CONUT
score has an effect on survival regardless of age and stage
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1.0

0.8

0.6

0.4

0.2

CONUT<2 (low)
CONUT≥2 (high)

0.0
.00

50.00

100.00

150.00

200.00

Survival (months)

Figure 3. Comparing progression free survival (PFS) and
CONUT score (< 2) and (≥ 2).

in patients with DLBCL. Our study showed that the
CONUT score in patients with DLBCL is a strong index
of poor prognosis.
5. Conclusion
We found that the high CONUT score is a useful indicator
of survival in DLBCL patients. The CONUT score is an
easy-to-calculate scoring method that can be performed
during routine blood draws from DLBCL patients. Our
study is one of the limited number of studies showing the
relationship between the CONUT score and prognostic
factors in DLBCL patients.
Our study shows that the CONUT score is an
independent, strong prognostic index in patients with
DLBCL. However, there is a need for prospective studies
with a larger sample size for long-term reliability and
acceptability.
5.1. Limitation
The present study was designed as a retrospective and
single centre study. In our study, the patients’ calorie
intake, nutritional status and body mass index at the time
of diagnosis were not specified as they were not recorded.

The cut-off value for the CONUT score was determined
based on the patients’ remission, refractory or relapse
status. The pathological phenotype of patients treated
with DA-REPOCH chemotherapy was non-germinal. Our
centre has been able to differentiate between germinal and
non-germinal types since 2017. This differentiation could
not be performed in patients with a diagnosis date before
2017.
5.2. Conflicts of interest
The authors declare no conflicts of interest.
5.3. Ethics approval
The present study was approved by the Institutional
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